Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Phase 1 Completed
40 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Phase 1 Completed
69 enrolled
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1 Completed
89 enrolled
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 Completed
136 enrolled
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Phase 1 Completed
285 enrolled
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
Phase 1 Completed
26 enrolled
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Phase 1 Completed
269 enrolled
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Phase 1 Completed
121 enrolled
MK-3475 Immunotherapy in Endometrial Carcinoma
Phase 1 Completed
10 enrolled 9 charts
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Phase 1 Completed
29 enrolled
DUET-3
Phase 1 Completed
198 enrolled
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Phase 1 Completed
22 enrolled
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates
Phase 1 Completed
33 enrolled
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer
Phase 1 Completed
12 enrolled
DUET-4
Phase 1 Completed
78 enrolled
DUET-2
Phase 1 Completed
150 enrolled
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Phase 1 Completed
26 enrolled
NP137
Phase 1 Completed
70 enrolled
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Phase 1 Completed
159 enrolled
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
Phase 1 Completed
53 enrolled
Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
Phase 1 Completed
72 enrolled
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Phase 1 Completed
6 enrolled 27 charts
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Phase 1 Completed
23 enrolled
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Phase 1 Completed
11 enrolled
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Phase 1 Completed
107 enrolled
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Phase 1 Completed
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
Phase 1 Completed
77 enrolled
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Phase 1 Completed
24 enrolled
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Phase 1 Completed
18 enrolled
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
Phase 1 Completed
77 enrolled
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
Phase 1 Completed
240 enrolled
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Phase 1 Completed
120 enrolled
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
Phase 1 Completed
24 enrolled
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Phase 1 Completed
32 enrolled
Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery
Phase 1 Completed
12 enrolled
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase 1 Completed
51 enrolled
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
19 enrolled
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
25 enrolled
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
25 enrolled
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Phase 1 Completed
58 enrolled
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
Phase 1 Completed
12 enrolled
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
38 enrolled
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
18 enrolled
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Phase 1 Completed
42 enrolled
Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
Phase 1 Completed
10 enrolled
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
Phase 1 Completed
33 enrolled
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
Phase 1 Completed
15 enrolled